By The Numbers

Top 15 MedTech Companies Ranked on 2022 R&D Spend

Again, Medtronic and J&J are securely in places 1 and 2, but Abbott Labs looks to be making a major investment in medtech in the near future, and is expected to gain both in CAGR and market share as a result.

Top 15 Drugs Ranked on 2022 Worldwide Sales

Finally, Evaluate looks at the individual products that will bring in the greatest revenue from here to 2022. They are dominated by oncologics (Revlimid, Keytruda, Opdivo, Ibrance and others), while HIV meds (Triumeq, Bictegravir) will also be in demand, as will autoimmune treatments (Humira), the pneumococcal medication Prevnar, and others. The only product on the list not aimed at a serious or life-threatening condition is Botox, originally prescribed for migraines but now largely used to erase facial lines and crows feet.

EvaluatePharma® delivers exclusive consensus sales forecasts and trusted commercial insight into biotech and pharmaceutical performance.

@EvaluatePharma

EvaluateMedTech® sets a new standard in commercial analysis and consensus forecasts of the global medical device and diagnostic industry.

@EvaluateMedTech

COMMENT

$6.5B

Patient Assistance Program spending by pharma

Pharmaceutical manufacturers poured over $6.5B into Patient Assistance Programs (PAPs) in 2014, the latest year for which there are statistics. PAPs make up 10 of the largest 15 U.S. charities and represent 8% of manufacturer operating costs. Source: The Foundation Center

84 million

Americans with prediabetes

The Centers for Disease Control and Prevention (CDC) estimates that about 84 million Americans have prediabetes, 90% of them undiagnosed and unaware. Highly treatable, this condition when unnoticed will lead to Type 2 diabetes in 5% to 10% of that population. Source: CDC,A Feasibility Study of Supply and Demand for Diabetes Prevention Programs in North Carolina, Volume 14, June 29, 2017 Compiled by Cari Kraft, Jacobs Management Group, Inc.

$1.06T

P rojectedsize of worldwide pharma market by2022

The total worldwide size of pharma sales is anticipated to reach $1.06 trillion by 2022, according to an EvaluatePharma analysis. This represents a Compound Annual Growth Rate (CAGR) of 6.5%. Orphan drugs are expected to represent $95B, or 32% of the increase in sales Source: EvaluatePharma, World Preview 2017, Outlook to 2022, July 2017

84%

of covered workers have prescription coverage choices

The Kaiser Family Foundation has found that nearly all (more than 99%) of workers who get employee healthcare coverage also have some form of prescription drug coverage, and that 84% have a choice of three, four or more tiers ofcost sharing for prescriptions. Source: Kaiser Family Foundation, 2016 Employer Health Benefits Survey, September 2016

66%

of MDs prefer email for industry news

Of all available communications platforms, 66% of doctors prefer email for accessing industry news, product updates and research opportunities. The same study found that 75% of NPs and PAs also prefer email. Source: Healthlink, Annual Healthcare Professional Communication Report 2017

Size of biologics market by 2022

EvaluatePharma expects biologics to contribute 52% of the top 100 product sales by 2022, which would represent over $550B in total worldwide sales. Roche is expected to be in the lead. Source: EvaluatePharma World Preview 2017, Outlook to 2022, July 2017

COMMENT $7.61B

E stimated size of global eClinicalsolutions market by 2022

Technological solutions in clinical research are growing at a rapid pace, and are expected to have a CAGR of 12.4% from now through 2022, reaching $7.61 billion. Electronic data capture (EDC) and clinical data management systems (CDMS) are currently the largest segments, but the electronic clinical outcome assessment (eCOA) area is expected to achieve the highest CAGR. Source: Markets and Markets, eClinicalSolutions Market by Product, April 2017